drugset / Trial / NCT00792363
Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS Mutations
Non-randomizedFactorialOpen-labelTreatment
Summary
The purpose of this study is to investigate the effect and the side effect profile of irinotecan and panitumumab administered every 3 weeks as 3rd line treatment for patients with metastatic colorectal cancer without KRAS mutations.
Timeline
- Start
- 2008-11
- Primary completion
- 2010-12
- Completion
- 2011-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 350 mg/m2 | Intravenous |
| Subject | Panitumumab | Monoclonal antibody | 9 mg/kg | Intravenous |